Alle Storys
Folgen
Keine Meldung von Polyphor AG mehr verpassen.

17.07.2018 – 07:09

Polyphor AG

EQS-Adhoc: Polyphor announces listing of new shares related to the convertible loan facility agreement with the Wellcome Trust


EQS Group-Ad-hoc: Polyphor AG / Key word(s): Miscellaneous
Polyphor announces listing of new shares related to the convertible loan
facility agreement with the Wellcome Trust

17-Jul-2018 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
Polyphor announces listing of new shares related to the convertible loan
facility agreement with the Wellcome Trust
 

Polyphor today announced that 15'758 new registered shares issued from the
authorized capital have been listed today on SIX Swiss Exchange. In April 2018
Polyphor and the Wellcome Trust entered into an amendment agreement to the
convertible loan facility agreement made available to Polyphor by the Wellcome
Trust. In this amendment agreement the Wellcome Trust exercised its right to
convert the outstanding loan amount in full immediately prior to the completion
of the listing of Polyphor's shares. These shares have a lock-up period ending
one year after the first day of trading.


For further information please contact:
Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email:IR@polyphor.com


About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company which has
discovered and is developing the OMPTA (Outer Membrane Protein Targeting
Antibiotics). The OMPTA are potentially the first new class of antibiotics
against Gram-negative bacteria to have reached phase III stage in the last 50
years. The company's lead product, murepavadin, (POL7080) is in Phase III
development against Pseudomonas aeruginosa - recognized as a critical priority 1
pathogen by WHO. Polyphor is also developing an immuno-oncology candidate,
balixafortide (POL6326), which has achieved clinical proof of concept in a Phase
Ib/proof of concept study in combination with eribulin in patients with advanced
breast cancer, and a pipeline of further preclinical antibiotics based on its
OMPTA platform. Polyphor is based in Allschwil near Basel and is listed on the
Swiss Stock Exchange (SIX: POLN). For more information, please visit
www.polyphor.com.

Additional features:


Document:http://n.eqs.com/c/fncls.ssp?u=FHWIMXVJWW
Document title: POLN_WT new shares_17.7.2018
--------------------------------------------------------------------------------
End of ad hoc announcement------------------------------------------------------

Language: English

Company:  Polyphor AG

          Hegenheimermattweg 125

          4123  Allschwil

          Switzerland

Phone:    +41 61 567 1600

Fax:      +41 61 567 1601

E-mail:info@polyphor.com

Internet: www.polyphor.com

ISIN:     CH0106213793

Listed:   SIX Swiss Exchange



 

End of Announcement EQS Group News Service

--------------------------------------------------------------------------------

705077  17-Jul-2018 CET/CEST